Loading clinical trials...

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

NCT04362644•University of Alabama at Birmingham

Summary

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Eligibility

Age

40 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age between 40-85 years old.
•2. A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
•3. Ability and willingness to give informed consent and adhere to study requirements.
•4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70.
•5. High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.

Exclusion Criteria

•1. Acute exacerbation of IPF within \<30 days
•2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
•3. Diagnoses of current infection by clinical or microbial assessments.
•4. Treatment for \>14 days within the preceding month with \>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
•5. Subjects with prior radiation therapy to the thorax.
•6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
•7. Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
•8. Subjects with known liver disease.
•9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
•10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
+1 more criteria

Locations (1)

The University of Alabama at Birmingham

Birmingham, Alabama, United States

Key Dates

Start Date

December 8, 2020

Primary Completion Date

June 1, 2027

Completion Date

June 1, 2027

Last Updated

July 14, 2025

Enrollment

ESTIMATED participants

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714

DRUG

Contacts

Jonathan McConathy, MD, PhD

CONTACT

205-996-7115 jmcconathy@uabmc.edu

April Riddle, BSRT

CONTACT

205-934-6504 ariddle@uabmc.edu

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis

View study

RECRUITINGPHASE3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Inclusion Criteria

Exclusion Criteria

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Validation of the C-mo System - Cough Monitoring